Demetrix Revenue and Competitors

Location

$61M

Total Funding

Cannabis

Industry

Estimated Revenue & Valuation

  • Demetrix's estimated annual revenue is currently $6.4M per year.(i)
  • Demetrix's estimated revenue per employee is $205,200
  • Demetrix's total funding is $61M.

Employee Data

  • Demetrix has 31 Employees.(i)
  • Demetrix grew their employee count by -42% last year.

Demetrix's People

NameTitleEmail/Phone
1
Manager, Regulatory AffairsReveal Email/Phone
2
Manager, EH&SReveal Email/Phone
3
Associate ScientistReveal Email/Phone
4
ScientistReveal Email/Phone
5
Senior Process EngineerReveal Email/Phone
6
Senior Director, Sales and Services (Cannabinoid Portfolio)Reveal Email/Phone
7
Automation EngineerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$7.1M33-40%N/AN/A
#2
$47.6M16420%$20MN/A
#3
$37.3M138-3%N/AN/A
#4
$10.1M490%$175.5MN/A
#5
$45.1M152-3%N/AN/A
#6
$23.8M889%N/AN/A
#7
$12.6M52-5%N/AN/A
#8
$86.5M2980%$12.3MN/A
#9
$2.4M15-12%N/AN/A
#10
$15.3M5142%$29MN/A
Add Company

What Is Demetrix?

Demetrix is named after Demeter, the Greek goddess of the harvest. Nature is our source and our inspiration. Many of today's medicines are derived from nature. Evolution has devised exquisite chemistry to produce compounds that interact with us, and our pathogens, with pin-point accuracy. Demetrix is harvesting billions of years of evolution to make the best, natural medicines in a smart and responsible way. Demetrix brings together world-class expertise to produce nature's medicines through fermentation. We work hard to find the best of nature's medicines and understand the genes that produce them. Then we carefully introduce those genes into domesticated microbes to make our medicines available to all who need them. Demetrix was founded in 2017 in the San Francisco Bay Area by esteemed bioengineer Jay Keasling and renowned biologist William Haseltine. We are honored to be backed by Horizons Ventures.

keywords:N/A

$61M

Total Funding

31

Number of Employees

$6.4M

Revenue (est)

-42%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Demetrix News

2022-04-20 - Demetrix talks rare cannabinoid ingredient and future of CBG ...

Demetrix recently announced commercial production of a rare cannabinoid, along with a partnership with ingredient supplier Evonik.

2022-04-19 - 20% CAGR Forecasted for CBG, Other Minor Cannabinoids ...

Demetrix Bio. Dreamstime Xxl 226350748. Research and Markets projects the U.S. market for minor cannabinoids—including cannabigerol (CBG),...

2022-03-30 - DEMETRIX AND EVONIK SIGN SUPPLY AGREEMENT FOR ...

Demetrix is a biotechnology company that believes in the power of science to make the world a better place. The company produces health and...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$6M31-3%N/A
#2
N/A32-3%N/A
#3
$6.4M32-3%N/A
#4
$3.7M333%N/A
#5
$3.9M34N/AN/A